Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

MDI-P demonstrates potent anti-HIV activity in preclinical studies

Aug. 28, 1998

Agouron's HIV protease inhibitor approved for marketing in Canada

Aug. 26, 1998

NIAID will collaborate with VaxGen on phase III AIDSVAX studies

Aug. 21, 1998

PKA I may be a valid target for immunomodulation in the HIV-infected patient

Aug. 18, 1998

Anti-HIV agents, protease inhibitors, patented by DuPont Merck

Aug. 14, 1998

Third center begins inoculating subjects in AIDSVAX trial

Aug. 12, 1998

Searle presents new HIV protease inhibitor series

Aug. 10, 1998

Japan Energy prepares HIV protease-inhibitory dipeptides

July 31, 1998

Celgene reports encouraging results from AIDS wasting study with Thalomid

July 30, 1998

Advanced Viral Research to initiate clinical trials with Reticulose in Mexico

July 28, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
GDE4 blockade promotes remyelination, study finds
BioWorld Science
Myelin is crucial for the correct functioning of nerve signaling and its loss is a feature of neurological disorders. The cells responsible for myelination in the...